An antifungal solution, a preparation method and use thereof are provided, belonging to the technical field of medicine. The antifungal solution includes an antifungal drug and a solvent as raw materials; where the antifungal drug and the solvent are at a mass ratio of (0.1-1):(18-318); and the solvent includes an ionic liquid, an alcohol organic solvent, and water. The ionic liquid has excellent solubility, skin penetration-promoting performance, and antifungal effect; the water can destroy an original polar network of the ionic liquid, forming smaller soluble ion groups, which greatly increase a miscibility window; the alcohol organic solvent can form a cosolvent with the ionic liquid and the water, thereby helping miscibility. The antifungal solution can ensure that the drug in a system is maintained in a dissolved state, thereby improving bioavailability and ensuring better therapeutic effects while reducing dosage.
A use of liquiritin in the preparation of a drug for treating atopic dermatitis. Animal experiments show that liquiritin can remarkably lessen the skin lesion severity of an atopic dermatitis mouse model, reduce the ear thickness and the epidermal thickness, and reduce the infiltration degree of dermal lymphocytes, thereby demonstrating that liquiritin has a significant therapeutic effect on atopic dermatitis, has no toxic and side effects on the liver, the spleen and the kidney, and has good clinical application prospects and enormous social benefits, and expanding a new application field for a conventional leguminous plant liquorice extract, i.e., liquiritin.
C07H 15/26 - Radicaux acycliques ou carbocycliques substitués par des hétérocycles
A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
3.
USE OF FORMONONETIN IN REDUCING IMIQUIMOD-INDUCED INFLAMMATORY CYTOKINE EXPRESSION BY MEANS OF INHIBITING INTERFERON SIGNALING PATHWAY
The use of formononetin (FMN) in reducing imiquimod (IMQ)-induced inflammatory cytokine expression by means of inhibiting an interferon (IFN) signaling pathway. The FMN can be used for the prevention and treatment of inflammatory skin diseases and the reduction of disease recurrence in the future. Using animal experiments combined with transcriptomics, it is found that the action of FMN on an IMQ-induced mouse model significantly improves inflammatory skin lesion symptoms, and inhibits pathological phenotypes such as the PASI score and epidermal hyperplasia in mice.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
4.
USE OF JAK-HADC DUAL-TARGET INHIBITOR AND DRUG FOR TREATING INFLAMMATORY SKIN DISEASES
The use of a JAK-HADC dual-target inhibitor and a drug for treating inflammatory skin diseases, which belong to the technical field of medicine. The use of a JAK-HADC dual-target inhibitor in the preparation of a drug for treating inflammatory skin diseases. The present invention relates to a compound or a stereoisomer or an optical isomer, a pharmaceutically acceptable salt, a prodrug, and a solvate thereof, in particular to the use of the compound as a JAK-HDAC dual-target inhibitor and an optional pharmaceutically acceptable carrier thereof in the treatment of JAK and HDAC-related inflammatory skin diseases, especially in the treatment of atopic dermatitis, psoriasis, vitiligo and alopecia areata.
Disclosed in the present invention is a novel use of a compound represented by formula (I), a proteolysis targeting chimera (PROTAC)-based Janus kinase (JAK) inhibitor, in the field of treating inflammatory skin diseases. The compound or a stereoisomer or an optical isomer, a pharmaceutically acceptable salt, a prodrug or a solvate thereof, a pharmaceutical composition comprising these compounds and a JAK inhibitor prepared from an optional pharmaceutically acceptable carrier of the pharmaceutical composition are used for blocking signaling of a pathway by targeted degradation of JAK, thus have the potential to treat atopic dermatitis or related skin diseases involving JAK, can ameliorate inflammatory skin diseases by inhibiting JAK, and develop new applications for JAK-PROTAC compounds, especially applications in the treatment of atopic dermatitis, psoriasis, vitiligo, and alopecia areata-related diseases.
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 8/49 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques contenant des composés hétérocycliques
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61Q 19/00 - Préparations pour les soins de la peau
A23L 33/10 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs
6.
USE OF LITHOSPERMIC ACID IN PREPARATION OF DRUGS USED FOR TREATING DIABETIC ULCERS
The use of lithospermic acid in preparation of drugs used for treating diabetic ulcers, belonging to the technical field of diabetic ulcer drugs. It is first proposed that the traditional Chinese medicine monomer lithospermic acid has the effect of treating diabetic ulcers. A mouse diabetic ulcer model and human keratinocyte cell line HaCaT are used to research the effects of lithospermic acid on the expression of diabetic ulcer healing indexes and inflammation indexes in mice and in-vitro cells, and the result shows that the lithospermic acid has remarkable treatment effects on diabetic ulcers, thus providing an important basis for clinical development of efficient diabetic ulcer treatment strategies and for preparation of drugs for treating diabetic ulcers in the future.
A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide condensés avec un carbocycle, p. ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
7.
ANTIFUNGAL SOLUTION, PREPARATION METHOD THEREFOR, AND USE THEREOF
The present invention belongs to the technical field of medicine, and particularly relates to an antifungal solution, a preparation method therefor, and use thereof. The present invention provides an antifungal solution. Raw materials for preparation comprise an antifungal medicament and a solvent; the mass ratio of the antifungal medicament to the solvent is (0.1-1):(18-318); the solvent comprises an ionic liquid, an alcohol organic solvent, and water. In the present invention, the ionic liquid has excellent dissolving capacity, skin permeability-promoting performance, and antifungal effect; the water can destroy the polar network of the original ionic liquid to form smaller soluble ionic groups, so that miscibility windows are greatly increased; the alcohol organic solvent can form a latent solvent with the ionic liquid and the water, thereby facilitating miscibility. The antifungal solution provided in the present invention can ensure that the medicament in the system is kept in a dissolved state, so that the bioavailability is improved, and it can be ensured that a better treatment effect can be obtained when the dose is reduced.
An external traditional Chinese medicine composition for treating psoriasis, comprising the following ingredients in parts by weight: 10 to 20 parts of Radix Rubiae, 10 to 20 parts of Radix Arnebiae, 10 to 20 parts of Common Selfheal Fruit-Spike, and 30 to 50 parts of raw Liquorice Root. All the medicinal ingredients in the traditional Chinese medicine composition synergistically have the effects of clearing away heat and toxic materials as well as cooling blood and dissipating blood stasis, and have a remarkable curative effect in external therapy of psoriasis.
A61K 36/30 - Boraginaceae (famille de la bourrache), p. ex. consoude, pulmonaire ou myosotis
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
Provided is use of Thonningianin A in the preparation of an antifungal drug synergist. When combined with an antifungal drug, Thonningianin A not only can reduce the dosage of the drug, but also ensure the treatment effect on fungal infection, such that the antifungal drug recovers the effect on drug-resistant fungi. Therefore, Thonningianin A can be used as a synergist of an antifungal drug, which can reduce the dosage of antifungal drugs such as azoles, echinocandins or polyenes, thereby reducing the toxic and side effects of the drug, and effectively treating the fungal infection, especially drug-resistant fungal infection. Moreover, the effect of the antifungal drug on candida tropicalis and cryptococcus neoformans can be enhanced.
A61K 31/7034 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
An ultra-sensitive digital rapid chromatographic assay system includes a chromatography system, an optical imaging system, and an image processing system. The chromatography system is a lateral flow or vertical flow chromatography system. The detection area on a reaction membrane of the chromatography system is immobilized with capture biological ligands, the analytes to be detected is specifically enriched by means of the captured biological ligands, and the analytes enriched in the detection area is specifically recognized by the detection biological ligands labelled with tracer nanoparticles. The optical imaging system can visualize a single tracer nanoparticle specifically bound on the reaction membrane. The image processing system includes a detection area recognition module and a nanoparticle counting module, and the counted number of tracer nanoparticles specifically binding to the detection area and the concentration of the analytes to be detected are a proportional relationship.
G01N 33/558 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet utilisant la diffusion ou la migration de l'anticorps ou de l'antigène
G01N 21/84 - Systèmes spécialement adaptés à des applications particulières
An ultra-sensitive digital rapid chromatographic detection system and method. Said detection system mainly comprises: a chromatography reaction system, an optical imaging system and an image processing system. The chromatography reaction system is a lateral or longitudinal chromatography reaction system, a bio-ligand is fixedly captured in a detection region on a reaction membrane (11) of the chromatography reaction system, an enriched analyte to be detected is specifically captured by means of the bio-ligand, and said analyte enriched in the detection region is specifically identified by a detection bio-ligand labeled with tracer nanoparticles; the optical imaging system can distinguish a single tracer nanoparticle specifically bound on the reaction membrane; and the image processing system comprises a detection region identification module and a counting module specifically bound to the tracer nanoparticles, the counted number of tracer nanoparticles specifically bound to the detection region and the concentration of said analyte being in a proportional relationship. The detection system and method can significantly improve the detection sensitivity of fluorescence or colloidal gold chromatographic analysis methods.
G01N 21/01 - Dispositions ou appareils pour faciliter la recherche optique
G01N 21/84 - Systèmes spécialement adaptés à des applications particulières
G01N 33/558 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet utilisant la diffusion ou la migration de l'anticorps ou de l'antigène
brevets
